Comparison Overview

BioLife Plasma Services

VS

MANKIND PHARMA LTD

BioLife Plasma Services

None, None, Bannockburn , Illinois , US, None
Last Update: 2026-01-25
Between 700 and 749

Every day at BioLife, we feel good knowing that what we do helps improve the lives of patients with rare diseases. While you focus on our donors, we’ll support you. We offer a purpose you can believe in, a team you can count on, opportunities for career growth, and a comprehensive benefits program, all in a fast-paced, friendly environment.

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 3,509
Subsidiaries: 0
12-month incidents
0
Known data breaches
1
Attack type number
1

MANKIND PHARMA LTD

Phase 3, New Delhi, IN
Last Update: 2026-01-20
Between 750 and 799

Mankind Pharma, one of the top 5 leading pharmaceutical companies in India, started its journey in 1995. Today, we have an employee base of over 20,000 and are racing towards $1 Billion. At Mankind, we aspire to aid the community in leading a healthy life by formulating, developing, commercializing, and delivering affordable and accessible medicines that satisfy urgent medical needs. We take great pride in the success of our products ranging from Pharma, OTC and FMCG brands like Manforce Condoms, Manforce Tablets, Manforce Staylong Gel, Unwanted 72, Prega News, Gas-O-Fast, Kaloree 1, Kabzend, Acne Star Gel and many others. Our operations are in 34 overseas destinations across Asia, Africa, South-East Asia, Gulf countries and CIS countries. Our Vision - To be a global pharmaceutical company, most admired for its Affordability, Quality and Accessibility of products. Our Mission - To be able to provide cost-effective, innovation based superior quality pharmaceutical products across the globe, to improve the lives of the patients. Mankind strongly believes and follows its Core Values: 𝐂𝐮𝐬𝐭𝐨𝐦𝐞𝐫 𝐂𝐞𝐧𝐭𝐫𝐢𝐜𝐢𝐭𝐲: Commitment to Customer - Internal and External 𝐐𝐮𝐚𝐥𝐢𝐭𝐲: It is in our DNA to maintain and deliver highest quality standards and products 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧: Intensely Research driven organization aiming at product innovation and technology improvements 𝐈𝐧𝐭𝐞𝐠𝐫𝐢𝐭𝐲: Always trustworthy, widely respected to be honest, and believed by everyone 𝐆𝐨 𝐁𝐞𝐲𝐨𝐧𝐝: Aim higher than capabilities 𝐏𝐞𝐨𝐩𝐥𝐞 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 𝐚𝐧𝐝 𝐂𝐨𝐥𝐥𝐚𝐛𝐨𝐫𝐚𝐭𝐢𝐨𝐧: Together we are foreseeing future and diligently stimulating our people in attaining goals

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 17,740
Subsidiaries: 0
12-month incidents
0
Known data breaches
0
Attack type number
0

Compliance Badges Comparison

Security & Compliance Standards Overview

https://images.rankiteo.com/companyimages/biolifeplasmaservices.jpeg
BioLife Plasma Services
ISO 27001
ISO 27001 certification not verified
Not verified
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
GDPR
GDPR certification not verified
Not verified
PCI DSS
PCI DSS certification not verified
Not verified
HIPAA
HIPAA certification not verified
Not verified
https://images.rankiteo.com/companyimages/mankind-pharma-ltd.jpeg
MANKIND PHARMA LTD
ISO 27001
ISO 27001 certification not verified
Not verified
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
GDPR
GDPR certification not verified
Not verified
PCI DSS
PCI DSS certification not verified
Not verified
HIPAA
HIPAA certification not verified
Not verified
Compliance Summary
BioLife Plasma Services
100%
Compliance Rate
0/4 Standards Verified
MANKIND PHARMA LTD
0%
Compliance Rate
0/4 Standards Verified

Benchmark & Cyber Underwriting Signals

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for BioLife Plasma Services in 2026.

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for MANKIND PHARMA LTD in 2026.

Incident History — BioLife Plasma Services (X = Date, Y = Severity)

BioLife Plasma Services cyber incidents detection timeline including parent company and subsidiaries

Incident History — MANKIND PHARMA LTD (X = Date, Y = Severity)

MANKIND PHARMA LTD cyber incidents detection timeline including parent company and subsidiaries

Notable Incidents

Last 3 Security & Risk Events by Company

https://images.rankiteo.com/companyimages/biolifeplasmaservices.jpeg
BioLife Plasma Services
Incidents

Date Detected: 1/2024
Type:Breach
Attack Vector: Credential Stuffing
Blog: Blog
https://images.rankiteo.com/companyimages/mankind-pharma-ltd.jpeg
MANKIND PHARMA LTD
Incidents

No Incident

FAQ

MANKIND PHARMA LTD company demonstrates a stronger AI Cybersecurity Score compared to BioLife Plasma Services company, reflecting its advanced cybersecurity posture governance and monitoring frameworks.

BioLife Plasma Services company has historically faced a number of disclosed cyber incidents, whereas MANKIND PHARMA LTD company has not reported any.

In the current year, MANKIND PHARMA LTD company and BioLife Plasma Services company have not reported any cyber incidents.

Neither MANKIND PHARMA LTD company nor BioLife Plasma Services company has reported experiencing a ransomware attack publicly.

BioLife Plasma Services company has disclosed at least one data breach, while the other MANKIND PHARMA LTD company has not reported such incidents publicly.

Neither MANKIND PHARMA LTD company nor BioLife Plasma Services company has reported experiencing targeted cyberattacks publicly.

Neither BioLife Plasma Services company nor MANKIND PHARMA LTD company has reported experiencing or disclosing vulnerabilities publicly.

Neither BioLife Plasma Services nor MANKIND PHARMA LTD holds any compliance certifications.

Neither company holds any compliance certifications.

Neither BioLife Plasma Services company nor MANKIND PHARMA LTD company has publicly disclosed detailed information about the number of their subsidiaries.

MANKIND PHARMA LTD company employs more people globally than BioLife Plasma Services company, reflecting its scale as a Pharmaceutical Manufacturing.

Neither BioLife Plasma Services nor MANKIND PHARMA LTD holds SOC 2 Type 1 certification.

Neither BioLife Plasma Services nor MANKIND PHARMA LTD holds SOC 2 Type 2 certification.

Neither BioLife Plasma Services nor MANKIND PHARMA LTD holds ISO 27001 certification.

Neither BioLife Plasma Services nor MANKIND PHARMA LTD holds PCI DSS certification.

Neither BioLife Plasma Services nor MANKIND PHARMA LTD holds HIPAA certification.

Neither BioLife Plasma Services nor MANKIND PHARMA LTD holds GDPR certification.

Latest Global CVEs (Not Company-Specific)

Description

Typemill is a flat-file, Markdown-based CMS designed for informational documentation websites. A reflected Cross-Site Scripting (XSS) exists in the login error view template `login.twig` of versions 2.19.1 and below. The `username` value can be echoed back without proper contextual encoding when authentication fails. An attacker can execute script in the login page context. This issue has been fixed in version 2.19.2.

Risk Information
cvss3
Base: 5.4
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:U/C:L/I:L/A:N
Description

A DOM-based Cross-Site Scripting (XSS) vulnerability exists in the DomainCheckerApp class within domain/script.js of Sourcecodester Domain Availability Checker v1.0. The vulnerability occurs because the application improperly handles user-supplied data in the createResultElement method by using the unsafe innerHTML property to render domain search results.

Description

A Remote Code Execution (RCE) vulnerability exists in Sourcecodester Modern Image Gallery App v1.0 within the gallery/upload.php component. The application fails to properly validate uploaded file contents. Additionally, the application preserves the user-supplied file extension during the save process. This allows an unauthenticated attacker to upload arbitrary PHP code by spoofing the MIME type as an image, leading to full system compromise.

Description

A UNIX symbolic link following issue in the jailer component in Firecracker version v1.13.1 and earlier and 1.14.0 on Linux may allow a local host user with write access to the pre-created jailer directories to overwrite arbitrary host files via a symlink attack during the initialization copy at jailer startup, if the jailer is executed with root privileges. To mitigate this issue, users should upgrade to version v1.13.2 or 1.14.1 or above.

Risk Information
cvss3
Base: 6.0
Severity: LOW
CVSS:3.1/AV:L/AC:L/PR:H/UI:N/S:U/C:N/I:H/A:H
cvss4
Base: 6.0
Severity: LOW
CVSS:4.0/AV:L/AC:L/AT:N/PR:H/UI:N/VC:N/VI:N/VA:N/SC:N/SI:H/SA:H/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

An information disclosure vulnerability exists in the /srvs/membersrv/getCashiers endpoint of the Aptsys gemscms backend platform thru 2025-05-28. This unauthenticated endpoint returns a list of cashier accounts, including names, email addresses, usernames, and passwords hashed using MD5. As MD5 is a broken cryptographic function, the hashes can be easily reversed using public tools, exposing user credentials in plaintext. This allows remote attackers to perform unauthorized logins and potentially gain access to sensitive POS operations or backend functions.